title: A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity.
abstract: We studied the pharmacokinetics and toxicity of 220 mg/m2 melphalan (HDM 220) followed by autologous stem cell transplantation in 16 patients with advanced haematological malignancies. Pharmacokinetic parameters (mean values of steady-state volume of distribution 14.6 l/m2, total body clearance 313 ml/min/m2, elimination half-life 46 min) were the same as those of 140 or 200 mg/m2 melphalan in previous reports. HDM 220 was feasible. Extramedullary toxicity was mainly W.H.O. grade 4 mucositis (13/16 patients). The median duration of 41 d (10, not reached) of thrombocytopenia < 25 x 10(9)/l was long. In multiple myeloma the response rate was 89% in heavily pretreated patients, suggesting that HDM 220 could be considered earlier in the course of the disease as an alternative consolidation therapy.
authors.affiliation: Department of Haematology, Nantes, France.
authors.forename: P
authors.initials: P
authors.lastname: Moreau
authors.forename: M F
authors.initials: MF
authors.lastname: Kergueris
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.forename: S
authors.initials: S
authors.lastname: Le Tortorec
authors.forename: B
authors.initials: B
authors.lastname: Mahé
authors.forename: C E
authors.initials: CE
authors.lastname: Bulabois
authors.forename: M J
authors.initials: MJ
authors.lastname: Rapp
authors.forename: C
authors.initials: C
authors.lastname: Larousse
authors.forename: R
authors.initials: R
authors.lastname: Bataille
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
mesh_terms: D000293:Adolescent; D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006689:Hodgkin Disease / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D010865:Pilot Projects; D014182:Transplantation, Autologous
chemical_list: D008558:Melphalan